MyFinsight
Home
Blog
About
Proceeds from maturities
and sales of...
$103,984K
Proceeds from milestone
obligations met and...
$2,508K
Proceeds from exercise of
common stock options...
$786K
(-77.03%↓ Y/Y)
Net cash and cash
equivalents provided by...
$41,572K
(-46.45%↓ Y/Y)
Net cash and cash
equivalents provided by...
$3,197K
(-6.58%↓ Y/Y)
Canceled cashflow
$62,412K
Net (decrease)
increase in cash and cash...
-$16,158K
(-2334.85%↓ Y/Y)
Canceled cashflow
$44,769K
Stock-based compensation
expense
$12,395K
(16.18%↑ Y/Y)
Accounts payable and
accrued liabilities
$10,524K
(-38.02%↓ Y/Y)
Other non-cash items
-$2,086K
Depreciation and
amortization expense
$416K
(-25.58%↓ Y/Y)
Inventories
-$13K
(-100.10%↓ Y/Y)
something is missing
-$42,500K
Purchases of short-term
investments,...
$19,912K
(-69.70%↓ Y/Y)
Net cash and cash
equivalents used in...
-$60,927K
(24.16%↑ Y/Y)
Canceled cashflow
$25,434K
something is missing
$71,817K
Total revenue
$33,658K
(42.08%↑ Y/Y)
Interest income
$1,605K
Net loss
-$62,339K
(20.91%↑ Y/Y)
Canceled cashflow
$107,080K
Accounts receivable
$20,630K
(43.51%↑ Y/Y)
Prepaid expenses and
other assets
$2,714K
(289.38%↑ Y/Y)
Accretion on investments,
net of amortization
$650K
(-81.04%↓ Y/Y)
Contract liability
-$28K
(88.33%↑ Y/Y)
Total segment
operating expenses-Sales...
$108,839K
Total segment
operating...
$20,092K
Total segment
operating...
$19,818K
Total segment
operating expenses-Cost...
$12,846K
(111.35%↑ Y/Y)
Interest expense
$2,479K
Total segment
operating...
$1,951K
(-20.50%↓ Y/Y)
Total segment
operating...
$1,886K
(-42.00%↓ Y/Y)
Total segment
operating...
$1,338K
(-33.70%↓ Y/Y)
Total segment
operating expenses-Other...
$170K
Back
Back
Cash Flow
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)
source: myfinsight.com